MPFC

SynQor® Releases a Military Grade Non-Isolated 3-Phase Power Factor Correction Module (MPFC-440-3PH-400-LE)

Retrieved on: 
Wednesday, November 2, 2022
MPFC, VDC, Efficiency, PFC, Vrms, GLOBE, PF, Revolution, Shock, Vibration

BOXBOROUGH, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- SynQor, Inc., announces its new military grade, 3-Phase Power Factor Correction Module ( MPFC-440-3PH-400-LE ).

Key Points: 
  • BOXBOROUGH, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- SynQor, Inc., announces its new military grade, 3-Phase Power Factor Correction Module ( MPFC-440-3PH-400-LE ).
  • The power conversion efficiency of this compact, military grade module is as high as 97%.
  • The 3-Phase PFC module is specifically designed for military naval applications but can also be used for ground systems.
  • This encased military grade component is designed to meet shock, vibration and environmental conditions as specified by MIL-STD-810G.

Curaleaf International to Present Positive Clinical and Pre-Clincial Research

Retrieved on: 
Thursday, October 20, 2022
Research, Finance, Cannabis, Clinical Trials, Professional Services, Alternative Medicine, Health, Science, Natural Resources, News, International, Dyspareunia, Imperial College London, University of Insubria, Migraine, Cannabis, Inflammation, Growth, Conference, Woman, Science, Curaleaf, Brain-derived neurotrophic factor, Genital wart, Patient, Grassroots, Lists of diseases, Research, VBD, BDNF, CNSX, International Medical School, University of Milan, University, Sex, Trial of the century, Company, Vulval vestibule, MPFC, ROS, CSE, Pain, Canadian Securities Exchange, Karger Publishers, OTCQX, ECS, Plasma, PMN, Brain, Reactive oxygen species, Title, Pharmaceutical industry, Drug, Audit, CBD, Cannabinoid, Select, Cannabidiol

MD., F. Vicariotto, Prof. MD and Barbara Pacchetti, Chief Scientific Officer at Curaleaf International.

Key Points: 
  • MD., F. Vicariotto, Prof. MD and Barbara Pacchetti, Chief Scientific Officer at Curaleaf International.
  • For further information on the preclinical research to be presented, please see the footnote at the end of this announcement.
  • Curaleaf International (formerly EMMAC Life Sciences Group) is Europes largest vertically integrated cannabis company, bringing together pioneering science and research with cutting-edge cultivation, extraction and production.
  • Curaleaf International assumes no obligation to update forward-looking statements should circumstances or management's estimates or opinions change.

New Path Emerging for Addressing Mental Health

Retrieved on: 
Monday, May 23, 2022
Consensus, Library, Memory, Patient, Putamen, Quality of life, Delusion, Even and odd functions, MPFC, Depression, Mental Health Awareness Month, Medicare, SAN, Brain, Bipolar, Perception, Cognition, Social cognition, University, Posit Science Corporation, Attention, Mental health, Government budget balance, Prefrontal cortex, Gait, Amygdala, CEO, GLOBE, Toy, Pharmaceutical industry, BDNF, Schizophrenia

The brain exercises used in the study are from the BrainHQ brain exercise app made by Posit Science .

Key Points: 
  • The brain exercises used in the study are from the BrainHQ brain exercise app made by Posit Science .
  • The findings add to a growing body of evidence that brain training may present a new path for addressing mental health a promising development during this month, which is Mental Health Awareness Month.
  • In a prior study , researchers found that patients with chronic schizophrenia who used BrainHQ showed gains in gamma-band activity.
  • We plan continue our work with researchers, regulators, and payers to advance this new path for addressing mental wellbeing.

Aptinyx Announces Publication in Molecular Psychiatry Demonstrating Reduction of Spontaneous Recovery of Fear with NYX-783

Retrieved on: 
Wednesday, April 20, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Inc., Annual report, Cognition, Fibromyalgia, Lewy body, SSRI, Fear, Government budget balance, PTSD, MPFC, Central and East European Center for Cognitive Science, Lists of disasters, U.S. Securities and Exchange Commission, Neuron, Post-traumatic stress disorder, Korea, Food, Human, Suicide, Lists of diseases, Center, Trauma, Brain, Central nervous system, Dementia, Private Securities Litigation Reform Act, Molecular Psychiatry, Regulation of tobacco by the U.S. Food and Drug Administration, Connective tissue disease, Responsibility, Patient, South Korea, Department, Form 10-K, Substance abuse, Assault, Prefrontal cortex, APTX, Yale School of Medicine, Trial of the century, Nasdaq, Arousal, NMDA, Sociality, NMDAR2B, Abuse, Mouse, Fast Track, Risk, Addiction, Institute, Basic research, Research, Pharmaceutical industry, Antibiotics, Meat

The publication, entitled "Positive modulation of N-methyl-D-aspartate receptors in the mPFC reduces the spontaneous recovery of fear," details the ability of NYX-783 to reduce fear-based behaviors in animal models of PTSD by measuring enhanced fear extinction and reduced spontaneous recovery (i.e., return) of fear.

Key Points: 
  • The publication, entitled "Positive modulation of N-methyl-D-aspartate receptors in the mPFC reduces the spontaneous recovery of fear," details the ability of NYX-783 to reduce fear-based behaviors in animal models of PTSD by measuring enhanced fear extinction and reduced spontaneous recovery (i.e., return) of fear.
  • These data suggest NYX-783 can inhibit the spontaneous recovery of learned fear even after exposure to an additional significant stressor.
  • The inhibition of spontaneous recovery of learned fear by NYX-783 results from increased NMDAR2B-mediated activity of neurons in the infralimbic medial prefrontal cortex.
  • These results elucidate the cellular targets of NYX-783 and the molecular mechanisms underlying the inhibition of spontaneous recovery.